Rating Change
Oppenheimer reiterated its Outperform rating on Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS) on August 12, 2026.
reiterateNASDAQ:TARS
Oppenheimer Reiterates Outperform Rating on Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
Oppenheimer reiterated its Outperform rating on Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS) on August 12, 2026.
At publication ·
What changed
Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS) · reiterate
- Firm
- Oppenheimer
- Rating
- Outperform to Outperform
- Price at event
- $70.02
- Market capitalization
- $3.5B
At a glance
Key takeaways
- Oppenheimer reiterated an Outperform rating on Tarsus Pharmaceuticals (TARS) on August 12, 2026, with the stock trading at $70.02 and a market capitalization of $3.5 billion.
Market Context
Tarsus Pharmaceuticals, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $70.02 with a market capitalization of $3.5B.
Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tarsus Pharmaceuticals, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tarsus Pharmaceuticals, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Oppenheimer | Outperform | N/A |
| Jul 31, 2026 | Mizuho | Outperform | N/A |
| Jul 21, 2026 | Guggenheim | Buy | N/A |
| Jul 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 04, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TARS Stock Page
Frequently Asked Questions
What does the Outperform rating mean for TARS?
A rating of Outperform from Oppenheimer reflects the analyst's outlook on Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TARS forecast page.